Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.44
PCRX's Cash-to-Debt is ranked lower than
54% of the 815 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.12 vs. PCRX: 1.44 )
Ranked among companies with meaningful Cash-to-Debt only.
PCRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.25  Med: 1.52 Max: No Debt
Current: 1.44
Equity-to-Asset 0.45
PCRX's Equity-to-Asset is ranked lower than
76% of the 739 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. PCRX: 0.45 )
Ranked among companies with meaningful Equity-to-Asset only.
PCRX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.82  Med: 0.45 Max: 0.66
Current: 0.45
-0.82
0.66
Piotroski F-Score: 3
Altman Z-Score: 3.63
Beneish M-Score: -3.24
WACC vs ROIC
14.75%
-26.68%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -15.64
PCRX's Operating Margin % is ranked lower than
79% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. PCRX: -15.64 )
Ranked among companies with meaningful Operating Margin % only.
PCRX' s Operating Margin % Range Over the Past 10 Years
Min: -325.77  Med: -126.13 Max: 3.8
Current: -15.64
-325.77
3.8
Net Margin % -19.26
PCRX's Net Margin % is ranked lower than
80% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.26 vs. PCRX: -19.26 )
Ranked among companies with meaningful Net Margin % only.
PCRX' s Net Margin % Range Over the Past 10 Years
Min: -300.62  Med: -133.77 Max: 0.75
Current: -19.26
-300.62
0.75
ROE % -23.29
PCRX's ROE % is ranked lower than
80% of the 792 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. PCRX: -23.29 )
Ranked among companies with meaningful ROE % only.
PCRX' s ROE % Range Over the Past 10 Years
Min: -558.91  Med: -54.49 Max: 0.95
Current: -23.29
-558.91
0.95
ROA % -12.46
PCRX's ROA % is ranked lower than
78% of the 821 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. PCRX: -12.46 )
Ranked among companies with meaningful ROA % only.
PCRX' s ROA % Range Over the Past 10 Years
Min: -82.83  Med: -46.36 Max: 0.52
Current: -12.46
-82.83
0.52
ROC (Joel Greenblatt) % -33.48
PCRX's ROC (Joel Greenblatt) % is ranked lower than
78% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.07 vs. PCRX: -33.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PCRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -251.5  Med: -116.71 Max: 8.96
Current: -33.48
-251.5
8.96
3-Year Revenue Growth Rate 42.30
PCRX's 3-Year Revenue Growth Rate is ranked higher than
95% of the 640 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. PCRX: 42.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PCRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -66.9  Med: -5.5 Max: 80.4
Current: 42.3
-66.9
80.4
3-Year EBITDA Growth Rate -34.20
PCRX's 3-Year EBITDA Growth Rate is ranked lower than
95% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. PCRX: -34.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PCRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -70.2  Med: -65.15 Max: -34.2
Current: -34.2
-70.2
-34.2
3-Year EPS without NRI Growth Rate -19.10
PCRX's 3-Year EPS without NRI Growth Rate is ranked lower than
82% of the 580 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.90 vs. PCRX: -19.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PCRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -68.6  Med: -65.6 Max: -19.1
Current: -19.1
-68.6
-19.1
» PCRX's 30-Y Financials

Financials (Next Earnings Date: 2017-08-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:HZNP, NAS:RDUS, OTCPK:EVTCY, NAS:SUPN, NAS:PAHC, NAS:MNTA, NAS:EGRX, NYSE:DPLO, NAS:IPXL, OTCPK:GNMLF, NAS:ENDP, OTCPK:KHTRF, OTCPK:NPPNY, NAS:SGYP, NAS:MDCO, OTCPK:TWMJF, OTCPK:CSWYF, NAS:INNL, NAS:IRWD, OTCPK:TZHGF » details
Traded in other countries:82P.Germany,
Headquarter Location:USA
Pacira Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the development, commercialization and manufacture of proprietary pharmaceutical products for use in hospitals and ambulatory surgery centers.

Pacira Pharmaceuticals is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and commercialization of pharmaceutical products, primarily for use in hospitals and ambulatory surgery centers. The company focuses its product candidates within the United States, and intends to out-license commercialization rights for other territories. Pacira aims to retain significant control over the development process and commercial execution for its product candidates.

Guru Investment Theses on Pacira Pharmaceuticals Inc

Baron Funds Comments on PaciraPharmaceuticals - Jan 18, 2017

Other companies we favor have wrapped intellectual property around an already proven pharmaceutical to create a new, protected franchise. The risk of not receiving approval for such products is significantly lower than for a typical bio-pharma investment. An example is PaciraPharmaceuticals, Inc. (NASDAQ:PCRX), whose FDA-approved medication is comprised of the pain killer bupivacaine combined with proprietary IP called Depo-Foam that enables its timed release. The product is appealing as it can in many cases eliminate the need for post-operative opiates and result in a shorter hospital stay.



From Baron Discovery Fund's Investing in Earlier Stage Small Cap Growth Companies January 2017.



Check out Ron Baron latest stock trades

Baron Funds Comments on Pacira Pharmaceuticals - Aug 10, 2016

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company that sells an injectable drug for local post-surgical analgesia (localized pain relief) called EXPAREL. In the fourth quarter of 2015, Pacira reached a very favorable resolution with the FDA concerning certain issues which had previously impeded its ability to market its drug to hospital customers. We re-established our investment in the company in the third quarter of 2015 as it appeared from public reports that the company was making significant progress on this front (and the FDA removed the warning letter from its site in September). Shares have been weak in the second quarter of 2016 as Pacira has not yet seen a re-acceleration in the growth of the drug (management has always guided to a late 2016 effect). In our opinion, Pacira still retains its large multi-billion dollar market opportunity, and we should start to see accelerating revenues by year-end.



From Baron Discovery Fund's second quarter 2016 commentary.





Check out Ron Baron latest stock trades

Baron Funds Comments on Pacira Pharmaceuticals Inc. - May 19, 2016

Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company that sells a drug for local surgical analgesia (an anesthetic) called EXPAREL. At the end of the third quarter of 2015, Pacira received a favorable resolution of certain FDA issues, and we re-established our investment at the lower levels caused by the prior regulatory uncertainty. In our opinion, shares were down in the first quarter due to the general negative industry dynamics around pharmaceutical companies.



From the Baron Global Advantage Fund first quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Pacira Pharmaceuticals Inc. - Feb 25, 2016

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company that sells a long-lasting pain medication called EXPAREL. This is an approved drug for local surgical analgesia (an anesthetic) that can be used for a multitude of soft tissue and orthopedic procedures. Ultimately, we believe that Pacira will obtain a nerve block indication for the drug as well. Effectively, Pacira has taken a generic drug called bupivacaine (under use for decades) and wrapped it with a special time release coating that allows analgesic effects to last for up to three days instead of just hours. This saves money for the health care system by allowing for earlier release of patients and much lower use of dangerous opioid pain killers. This wrapper technology can be used for other drugs, and the company is developing a number of these which could bring additional upside to valuation. We were prior owners of Pacira, but sold the investment at much higher levels when we grew concerned about regulatory issues with the FDA that cropped up at the end of 2014. Shares dropped considerable after that. By the end of the third quarter, we anticipated a favorable resolution of these issues after the FDA removed the warning letter from its website (a highly unusual event), and we re-established our investment at the lower levels caused by the regulatory uncertainty. In the fourth quarter, Pacira resolved all of its marketing issues with the FDA via a formal agreement. This could allow for accelerated growth in 2016. Run rate sales of EXPAREL are now about $250 million and the market could be worth billions. Pacira has the potential for years of continued growth.



From Baron Discover Fund's fourth quarter 2015 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Pacira Pharmaceuticals Inc

Pacira Pharmaceuticals Appoints Mark I. Froimson, M.D., to Board of Directors
Pacira Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
Pacira Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference
Mariko Gordon Finds Value in Small and Midcap Stocks Guru stands apart with her successful, concentrated portfolios of small and midcap value stocks
Mariko Gordon (Trades, Portfolio) founded her own investment advisory firm some 22 years ago and went on to become an investment guru through small and midcap stock picks. Read more...
Pacira Pharmaceuticals Announces Resignation of James Scibetta
Paul Tudor Jones’ Top 4 Health Care Buys Guru invested in multiple health care stocks in 1st quarter
Paul Tudor Jones (Trades, Portfolio)’ Tudor Investment Corp. gained 325 new holdings during the first quarter. Among his purchases were multiple health care stocks including VCA Inc. (NASDAQ:WOOF), DaVita Inc. (NYSE:DVA), Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) and Edwards Lifesciences Corp. (NYSE:EW). Read more...
Pacira Pharmaceuticals to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference
New Research Shows Vast Majority of Oral Surgery Patients Would Choose Non-opioid Medication to Treat Postsurgical Pain if Given the Option
Pacira Pharmaceuticals Announces Timing for First Quarter 2017 Financial Results Webcast and Conference Call
MonoSol Rx Appoints James S. Scibetta to Board of Directors

Ratios

vs
industry
vs
history
Forward PE Ratio 714.29
PCRX's Forward PE Ratio is ranked lower than
100% of the 68 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.46 vs. PCRX: 714.29 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 6.97
PCRX's PB Ratio is ranked lower than
85% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. PCRX: 6.97 )
Ranked among companies with meaningful PB Ratio only.
PCRX' s PB Ratio Range Over the Past 10 Years
Min: 3.47  Med: 9.85 Max: 73.42
Current: 6.97
3.47
73.42
PS Ratio 6.33
PCRX's PS Ratio is ranked lower than
72% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. PCRX: 6.33 )
Ranked among companies with meaningful PS Ratio only.
PCRX' s PS Ratio Range Over the Past 10 Years
Min: 0.39  Med: 11.75 Max: 30.46
Current: 6.33
0.39
30.46
Price-to-Free-Cash-Flow 115.11
PCRX's Price-to-Free-Cash-Flow is ranked lower than
86% of the 209 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.35 vs. PCRX: 115.11 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PCRX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 103.17  Med: 373.33 Max: 1380.35
Current: 115.11
103.17
1380.35
Price-to-Operating-Cash-Flow 48.22
PCRX's Price-to-Operating-Cash-Flow is ranked lower than
83% of the 281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.13 vs. PCRX: 48.22 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PCRX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 33.8  Med: 80.76 Max: 894.45
Current: 48.22
33.8
894.45
Current Ratio 9.81
PCRX's Current Ratio is ranked higher than
91% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. PCRX: 9.81 )
Ranked among companies with meaningful Current Ratio only.
PCRX' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 1.7 Max: 10.16
Current: 9.81
0.81
10.16
Quick Ratio 9.15
PCRX's Quick Ratio is ranked higher than
91% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. PCRX: 9.15 )
Ranked among companies with meaningful Quick Ratio only.
PCRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.68  Med: 1.4 Max: 9.31
Current: 9.15
0.68
9.31
Days Inventory 142.75
PCRX's Days Inventory is ranked lower than
64% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.36 vs. PCRX: 142.75 )
Ranked among companies with meaningful Days Inventory only.
PCRX' s Days Inventory Range Over the Past 10 Years
Min: 31.07  Med: 75.65 Max: 230.95
Current: 142.75
31.07
230.95
Days Sales Outstanding 36.09
PCRX's Days Sales Outstanding is ranked higher than
83% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.70 vs. PCRX: 36.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
PCRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 29.85  Med: 40.64 Max: 67.76
Current: 36.09
29.85
67.76
Days Payable 29.90
PCRX's Days Payable is ranked lower than
86% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.86 vs. PCRX: 29.90 )
Ranked among companies with meaningful Days Payable only.
PCRX' s Days Payable Range Over the Past 10 Years
Min: 20.45  Med: 44.4 Max: 246.51
Current: 29.9
20.45
246.51

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.70
PCRX's 3-Year Average Share Buyback Ratio is ranked higher than
53% of the 477 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. PCRX: -3.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PCRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -288.4  Med: -138 Max: -3.7
Current: -3.7
-288.4
-3.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 34.71
PCRX's Price-to-Net-Cash is ranked lower than
80% of the 243 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.42 vs. PCRX: 34.71 )
Ranked among companies with meaningful Price-to-Net-Cash only.
PCRX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 14.45  Med: 38.67 Max: 1773.2
Current: 34.71
14.45
1773.2
Price-to-Net-Current-Asset-Value 15.89
PCRX's Price-to-Net-Current-Asset-Value is ranked lower than
78% of the 521 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.35 vs. PCRX: 15.89 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PCRX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 10.03  Med: 33.98 Max: 414.29
Current: 15.89
10.03
414.29
Price-to-Tangible-Book 8.49
PCRX's Price-to-Tangible-Book is ranked lower than
81% of the 701 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.54 vs. PCRX: 8.49 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PCRX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 5.1  Med: 13.64 Max: 99.7
Current: 8.49
5.1
99.7
Price-to-Median-PS-Value 0.54
PCRX's Price-to-Median-PS-Value is ranked higher than
90% of the 718 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.08 vs. PCRX: 0.54 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PCRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.03  Med: 1.08 Max: 2.16
Current: 0.54
0.03
2.16
Earnings Yield (Greenblatt) % -2.59
PCRX's Earnings Yield (Greenblatt) % is ranked lower than
74% of the 820 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. PCRX: -2.59 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PCRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -72.7  Med: -2.7 Max: 1.2
Current: -2.59
-72.7
1.2

More Statistics

Revenue (TTM) (Mil) $280.18
EPS (TTM) $ -1.43
Beta2.18
Short Percentage of Float8.36%
52-Week Range $29.95 - 58.95
Shares Outstanding (Mil)40.09

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 306 406 525
EPS ($) 0.11 1.82 3.68
EPS without NRI ($) 0.11 1.82 3.68
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for PCRX

Headlines

Articles On GuruFocus.com
Pacira Pharmaceuticals Appoints Mark I. Froimson, M.D., to Board of Directors Jun 15 2017 
Pacira Pharmaceuticals to Present at the JMP Securities Life Sciences Conference Jun 14 2017 
Pacira Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference Jun 01 2017 
Mariko Gordon Finds Value in Small and Midcap Stocks May 30 2017 
Pacira Pharmaceuticals Announces Resignation of James Scibetta May 23 2017 
Paul Tudor Jones’ Top 4 Health Care Buys May 18 2017 
Pacira Pharmaceuticals to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference May 10 2017 
New Research Shows Vast Majority of Oral Surgery Patients Would Choose Non-opioid Medication to Trea May 03 2017 
Pacira Pharmaceuticals Announces Timing for First Quarter 2017 Financial Results Webcast and Confere Apr 27 2017 
MonoSol Rx Appoints James S. Scibetta to Board of Directors Apr 11 2017 

More From Other Websites
Pacira Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PCRX-US : June... Jun 22 2017
Pacira Pharmaceuticals Appoints Mark I. Froimson, M.D., to Board of Directors Jun 15 2017
Pacira Pharmaceuticals to Present at the JMP Securities Life Sciences Conference Jun 14 2017
Opioids are ravaging the U.S., but they’re still the best pain drug we’ve got Jun 09 2017
Why Is Pacira (PCRX) Down 4.5% Since the Last Earnings Report? Jun 09 2017
Pacira Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference Jun 01 2017
Pacira Pharmaceuticals Announces Resignation of James Scibetta May 23 2017
ETFs with exposure to Pacira Pharmaceuticals, Inc. : May 22, 2017 May 22 2017
Pacira Pharmaceuticals, Inc. :PCRX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017 May 19 2017
Paul Tudor Jones' Top 4 Health Care Buys May 18 2017
Edited Transcript of PCRX earnings conference call or presentation 4-May-17 12:30pm GMT May 10 2017
Pacira Pharmaceuticals to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference May 10 2017
Pacira Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PCRX-US : May... May 08 2017
Pacira reports 1Q loss May 04 2017
Pacira Pharmaceuticals, Inc. Reports First Quarter 2017 Financial Results May 04 2017
Investor Network: Pacira Pharmaceuticals, Inc. to Host Earnings Call May 04 2017
New Research Shows Vast Majority of Oral Surgery Patients Would Choose Non-opioid Medication to... May 03 2017
Pacira Pharmaceuticals Announces Timing for First Quarter 2017 Financial Results Webcast and... Apr 27 2017
Pacira Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PCRX-US :... Apr 25 2017
Can Pacira Pharmaceuticals' Exparel Reduce Opioid Abuse? Apr 19 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}